ALSFRS‐R

@article{Gordon2004ALSFRSR,
  title={ALSFRS‐R},
  author={Paul H. Gordon and Robert G. Miller and D. Moore},
  journal={Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders},
  year={2004},
  volume={5},
  pages={90 - 93}
}
The ALSFRS‐R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimizes dropout, reduces cost, and correlates with survival. Unlike the other standard outcome measures currently employed, the ALSFRS‐R is also a measure of global function. 
Primary lateral sclerosis (PLS) functional rating scale: PLS‐specific clinimetric scale
Our research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS).
Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients
TLDR
ALSFRS-R is an important tool to assess functional UL involvement in ALS, however, it can mislead clinicians when evaluating right-handed patients with initial LUL onset form. Expand
Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis
TLDR
Collection of PROMs is feasible in the context of routine ALS care and PROM scores are highly correlated with validated ALS outcome measures. Expand
Validation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale in Poland and its reliability in conditions of the medical experiment
TLDR
Validation of the Polish version of the ALSFRS-R supports the reliability and internal consistency of scale and proved also to be a proper tool for monitoring the course of the experimental medical therapy for patients with ALS. Expand
Clinical Measures of Bulbar Dysfunction in ALS
TLDR
A comprehensive appraisal of the most commonly utilized clinical tools for assessing and monitoring bulbar dysfunction in ALS based on the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) evaluation framework is provided. Expand
Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study
TLDR
The evaluation of number of body regions involved (NBRI) at diagnosis, with the inclusion of initial respiratory/thoracic involvement and cognition, can be useful in many research fields, improving the stratification of patients. Expand
Effects of prolonged interruption of rehabilitation routines in amyotrophic lateral sclerosis patients.
TLDR
Prolonged interruption of rehabilitation during the lockdown may have accelerated the functional decline in ALS patients' motor skills with as measured after 2 months by the ALSFRS-R in the limb and bulbar subscores, but not respiratory subscore. Expand
Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis
TLDR
The ALSFRS-R fails to satisfy rigorous measurement standards and should be revised, at least in part, revised. Expand
Outcome of patients with amyotrophic lateral sclerosis attending in a multidisciplinary care unit.
TLDR
The treatment in multidisciplinary units does not change the neurological progression of the disease, but increases the survival of ALS patients regardless of their initial onset, emphasising the use of multi-disciplinary care. Expand
Functional status and oral health in patients with amyotrophic lateral sclerosis: A cross-sectional study.
TLDR
Findings showed that a poor oral health status might be correlated to a worse functional status and survival time, and an adequate oral health care and rehabilitation should be considered as crucial in the multidisciplinary management of patients with ALS. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 15 REFERENCES
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
TLDR
A revised version of the ALSFRS, which incorporates additional assessments of dyspnea, orthopnea, and the need for ventilatory support is validated, indicating that the quality of function is a strong determinant of quality of life in ALS. Expand
Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials
TLDR
The data provided by the placebo patients who participated in the ALS CNTF Treatment Study (ACTS) is used to demonstrate the robustness, test-retest reliability and consistency of the ALSFRS as employed in a large, multicenter clinical trial. Expand
Amyotrophic lateral sclerosis severity scale.
TLDR
The amyotrophic lateral sclerosis severity scale has been shown to have an average estimated reliability coefficient of 0.95 between examiners and speech ratings were correlated greater than 0.80 for objective speech measures. Expand
Unified Huntington's disease rating scale: A follow up
TLDR
The authors suggest performing a total UHDRS evaluation every second year for every HD patient as part of the routine longitudinal evaluation. Expand
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
TLDR
A more rapid disease progression rate while receiving placebo treatment was predictive of a significantly stronger patient response to rivastigmine therapy, and this relation was observed with the other 3 outcome measures and was still apparent when accounting for disease severity. Expand
Phase II/II/III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
  • Neurology
  • 2001
ACTS) Group
  • A double-blind, placebo controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology
  • 1996
ALSFRS as a measure of disease progression and a predictor of survival
  • In preparation,
  • 2003
Variability in ALS functional rating scale scores
  • Preparation,
  • 2003
A controlled trial of recombinant-methionyl BDNF (r-metHuBDNF) in ALS
  • Neurology
  • 1999
...
1
2
...